Suppr超能文献

天然细胞外囊泡在人诱导多能干细胞向心肌细胞分化中的生物活性和 miRNA 谱分析。

Bioactivity and miRNome Profiling of Native Extracellular Vesicles in Human Induced Pluripotent Stem Cell-Cardiomyocyte Differentiation.

机构信息

iBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, Oeiras, 2781-901, Portugal.

ITQB-NOVA, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Av. da República, Oeiras, 2780-157, Portugal.

出版信息

Adv Sci (Weinh). 2022 May;9(15):e2104296. doi: 10.1002/advs.202104296. Epub 2022 Mar 24.

Abstract

Extracellular vesicles (EV) are an attractive therapy to boost cardiac regeneration. Nevertheless, identification of native EV and corresponding cell platform(s) suitable for therapeutic application, is still a challenge. Here, EV are isolated from key stages of the human induced pluripotent stem cell-cardiomyocyte (hiPSC-CM) differentiation and maturation, i.e., from hiPSC (hiPSC-EV), cardiac progenitors, immature and mature cardiomyocytes, with the aim of identifying a promising cell biofactory for EV production, and pinpoint the genetic signatures of bioactive EV. EV secreted by hiPSC and cardiac derivatives show a typical size distribution profile and the expression of specific EV markers. Bioactivity assays show increased tube formation and migration in HUVEC treated with hiPSC-EV compared to EV from committed cell populations. hiPSC-EV also significantly increase cell cycle activity of hiPSC-CM. Global miRNA expression profiles, obtained by small RNA-seq analysis, corroborate an EV-miRNA pattern indicative of stem cell to cardiomyocyte specification, confirming that hiPSC-EV are enriched in pluripotency-associated miRNA with higher in vitro pro-angiogenic and pro-proliferative properties. In particular, a stemness maintenance miRNA cluster upregulated in hiPSC-EV targets the PTEN/PI3K/AKT pathway, involved in cell proliferation and survival. Overall, the findings validate hiPSC as cell biofactories for EV production for cardiac regenerative applications.

摘要

细胞外囊泡 (EV) 是一种很有吸引力的治疗方法,可以促进心脏再生。然而,鉴定天然 EV 及其适合治疗应用的相应细胞平台仍然是一个挑战。在这里,我们从人类诱导多能干细胞-心肌细胞 (hiPSC-CM) 分化和成熟的关键阶段分离 EV,即从 hiPSC (hiPSC-EV)、心脏祖细胞、未成熟和成熟的心肌细胞中分离 EV,目的是确定一个有前途的 EV 生产细胞工厂,并确定生物活性 EV 的遗传特征。hiPSC 和心脏衍生物分泌的 EV 显示出典型的大小分布特征和特定的 EV 标志物表达。生物活性测定显示,与来自定向细胞群的 EV 相比,用 hiPSC-EV 处理的 HUVEC 形成管和迁移的能力增加。hiPSC-EV 还显著增加 hiPSC-CM 的细胞周期活性。通过小 RNA-seq 分析获得的全球 miRNA 表达谱证实了 EV-miRNA 模式表明干细胞向心肌细胞特化,这证实了 hiPSC-EV 富含与体外更强的促血管生成和促增殖特性相关的多能性相关 miRNA。特别是,在 hiPSC-EV 中上调的一个维持干细胞特性的 miRNA 簇靶向参与细胞增殖和存活的 PTEN/PI3K/AKT 途径。总的来说,这些发现验证了 hiPSC 作为 EV 生产的细胞工厂,用于心脏再生应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e110/9130911/3265a193f3c0/ADVS-9-2104296-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验